Intellia Therapeutics CEO John Leonard has, for the last couple years, found himself stuck in a financial Groundhog Day. Repeatedly, the company has announced positive data from its gene editing trials, only to watch the stock slide.
The stock market is notoriously fickle, particularly around buzzy gene-editing companies. Yet the selloffs pointed to real questions around the biotech’s programs: Clearly, its CRISPR-based drugs were effective. But were they any more effective than other drugs that use older, less sci-fi technologies?
Intellia tried to allay some of those concerns on Saturday with new year-long data from the 36 patients treated in an early trial of its CRISPR drug for ATTR cardiomyopathy.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in